Question 1

What is Erlotinib?

Accepted Answer

Erlotinib is a type of medication known as a kinase inhibitor. It works by targeting and blocking the activity of a specific protein called epidermal growth factor receptor (EGFR), which is found on the surface of some cells.

This protein plays a role in the signaling pathways that regulate cell growth and division. By interfering with these signals, erlotinib helps to slow or stop the growth and spread of cancer cells.

Question 2

What is Erlotinib used for?

Accepted Answer

Erlotinib is used to treat EGFR mutation-positive non-small cell lung cancer and pancreatic cancer .

Question 3

How does Erlotinib work?

Accepted Answer

Mechanism of Action

Erlotinib belongs to a class of medications called tyrosine kinase inhibitors. It is designed to target and block the activity of a protein called the epidermal growth factor receptor (EGFR). This protein is found on the surface of both normal cells and cancer cells.

In certain types of cancer, the EGFR protein is overactive or mutated, sending continuous signals to the cell to grow, divide, and spread. By attaching to this protein, erlotinib interferes with these signals. This process helps to:

Slow down the growth of the tumor.

Stop cancer cells from multiplying.

Prevent the cancer from spreading to other parts of the body.

Because erlotinib targets specific proteins involved in cell growth, it is considered a targeted therapy rather than a traditional chemotherapy, which typically affects all rapidly dividing cells in the body.

Question 4

What are the brand names for Erlotinib?

Accepted Answer

Erlotinib is sold under the brand name Tarceva .

Question 5

What are the active ingredients in Erlotinib?

Accepted Answer

The active ingredient in Erlotinib is erlotinib .

Question 6

What are the side effects of Erlotinib?

Accepted Answer

Common side effects of Erlotinib may include:

Rash

Diarrhea

Loss of appetite

and others.

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Erlotinib?

Accepted Answer

Erlotinib belongs to the EGFR tyrosine kinase inhibitor drug class.

Question 8

What is the dosage of Erlotinib and how do I take it?

Accepted Answer

How to Take Erlotinib

Erlotinib is a tablet taken by mouth, usually once a day. It must be taken on an empty stomach, which means at least one hour before or two hours after eating any food. Swallow the tablets whole with water; do not crush, chew, or break them.

Missed Doses

If you miss a dose of erlotinib, take it as soon as you remember. If it is nearly time for your next dose, skip the missed dose and return to your regular schedule. Do not take extra medicine or two doses at once to make up for a missed dose.

Special Instructions

Grapefruit: Avoid consuming grapefruit or grapefruit juice while using this medication, as it may interfere with how the drug is processed.

Stomach Acid Reducers: Certain medications used to treat heartburn or stomach acid can interfere with how erlotinib is absorbed. You may need to take erlotinib several hours before or after taking these types of drugs.

Consistency: Take your dose at the same time each day to help maintain a steady level of the medication in your body.

Question 9

Is Erlotinib safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Erlotinib may cause fetal harm when administered to a pregnant woman. Animal studies have shown that the medication can increase the risk of pregnancy loss and result in lower birth weights. Because of these risks, healthcare providers typically advise that erlotinib should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Individuals who can become pregnant are advised to use effective contraception during treatment and for at least one month after the final dose. If a patient becomes pregnant while taking this medication, they should contact their healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not known whether erlotinib passes into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment and for at least two weeks after the final dose. Patients should consult with their healthcare team to discuss the best way to feed their infant during and after treatment.

Question 10

What forms and strengths does Erlotinib come in?

Accepted Answer

Dosage Forms

Erlotinib is provided as a tablet for oral administration. These tablets are film-coated and are intended to be swallowed whole.

Oral tablet

Question 11

What is the FDA approval status of Erlotinib?

Accepted Answer

FDA Approval History

Erlotinib was first approved by the U.S. Food and Drug Administration (FDA) in November 2004. It was initially indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one prior chemotherapy regimen. Over time, the FDA updated its indications to focus on patients whose tumors harbor specific genetic mutations.

Approved Indications

The FDA has approved erlotinib for the following specific uses:

Non-Small Cell Lung Cancer (NSCLC): It is used as a first-line treatment, maintenance treatment, or second-line treatment for patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Combination Therapy for NSCLC: In 2020, the FDA approved erlotinib for use in combination with ramucirumab for the first-line treatment of metastatic NSCLC in patients with specific EGFR mutations.

Pancreatic Cancer: It is approved for use in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer.

Regulatory Status and Safety

Erlotinib is a prescription-only medication. It does not currently require a Risk Evaluation and Mitigation Strategy (REMS) program. While the medication does not carry a Boxed Warning, the FDA requires the manufacturer to include warnings regarding serious potential risks, including interstitial lung disease, renal failure, hepatotoxicity (liver toxicity), and gastrointestinal perforation. Generic versions of erlotinib tablets are FDA-approved and available.

Question 12

What should I know about Erlotinib and cost?

Accepted Answer

Generic and Brand-Name Availability

Erlotinib is available as a generic medication and under the brand name Tarceva. Generic versions are typically more affordable than brand-name drugs. Choosing the generic form, when available and approved by a healthcare provider, can significantly reduce out-of-pocket expenses.

Insurance and Medicare Coverage

Most insurance plans, including Medicare Part D and Medicare Advantage, provide coverage for erlotinib. However, because it is a specialty oncology medication, it is often placed on a higher cost-sharing tier. This may result in a higher copayment or coinsurance amount. Many insurance companies also require prior authorization before they will approve coverage for the medication.

Financial Assistance Programs

For patients who are uninsured or have high out-of-pocket costs, several resources may be available:

Manufacturer Assistance: Pharmaceutical companies that produce erlotinib may offer patient assistance programs or copay savings cards to eligible individuals.

Support Foundations: Non-profit organizations sometimes provide financial grants to help cancer patients cover the costs of specialty treatments.

Patients are encouraged to speak with their oncology team or a specialty pharmacist to explore available financial support options and to verify coverage details with their insurance provider.

Erlotinib

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?